DelveInsight’s, “Glioma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline ...

Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...

A bill under consideration in the legislature would position Iowa to immediately allow prescriptions of a synthetic version ...

ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the ...

Raziel Green, 52, an active runner and mother of two, was diagnosed with a rare form of ALS in 2017. Since starting a ...

These fibrils form the ... “This FDA approval provides an opportunity to further transform ATTR-CM treatment with a new mechanism of action. The HELIOS-B clinical trial found that vutrisiran ...

FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably ...

“This FDA approval provides an opportunity to further transform ATTR-CM treatment with a new mechanism of action. The HELIOS-B clinical trial found that vutrisiran allowed patients to live ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

A clinical trial is typically the first look at how an ... These data inform Character’s approach to targets for the dry form of age-related macular degeneration and they also indicate which ...

Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

Biopharmaceutical company Rezolute, which develops treatments for a rare, congenital form ... trials. This, Verve claims, could “delay or prevent” certain drug from ever getting FDA approval.